Amanote Research
Register
Sign In
Figure 1: FDA Approved Integrase Strand Transfer Inhibitors INSTIs: Raltegravir, Elvitegravir and Dolutegravir.
doi 10.7717/peerj-pchem.6/fig-1
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
PeerJ
Related search
HIV-1 Integrase Strand Transfer Inhibitors Stabilize an Integrase–Single Blunt-Ended DNA Complex
Journal of Molecular Biology
Structural Biology
Molecular Biology
Biophysics
Prevalence of HIV-1 Integrase Mutations Related to Resistance to Dolutegravir in Raltegravir Naïve and Pretreated Patients
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals During Pregnancy
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors
Drug Metabolism and Disposition
Pharmacology
Pharmaceutical Science
Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients With Nucleoside Reverse Transcriptase Inhibitor Resistance
AIDS Research and Human Retroviruses
Virology
Infectious Diseases
Immunology
HIV1 Integrase Strand Transfer Inhibitors With Reduced Susceptibility to Drug Resistant Mutant Integrases
Preclinical Evaluation of 1h-Benzylindole Derivatives as Novel Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
FDA-Approved Biosimilar Insulin
Journal of diabetes science and technology
Internal Medicine
Endocrinology
Bioengineering
Biomedical Engineering
Metabolism
Diabetes
